Is a
Patent attributes
Patent Jurisdiction
Patent Number
Date of Patent
August 13, 2019
Patent Application Number
15656390
Date Filed
July 21, 2017
Patent Citations Received
Patent Primary Examiner
Patent abstract
The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
